DSIP

DSIP (Delta Sleep-Inducing Peptide) — 5mg Research Overview

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Originally isolated from rabbit cerebral venous blood by Monnier and colleagues in 1977, DSIP was named for its striking ability to induce slow-wave (delta) sleep patterns in experimental animals when administered intracerebrally. Decades of subsequent research have revealed DSIP to be a pleiotropic signaling molecule with wide-ranging biological activities extending far beyond sleep regulation, including roles in stress modulation, neuroendocrine control, neuroprotection, antioxidant defense, and pain processing. The synthetic form is available as a lyophilized powder for qualified laboratory and preclinical research purposes.

---

Molecular Identity and Physical Characteristics

DSIP is classified as a neuropeptide and belongs to the family of naturally occurring bioactive oligopeptides. Its core structural features include:

- **Sequence:** H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH - **Residue count:** 9 amino acids (nonapeptide) - **Molecular formula:** C₃₅H₄₈N₁₀O₁₅ - **Molecular weight:** 849.86 Da - **CAS Registry:** 62568-57-4 - **Physical form (synthetic):** White to off-white lyophilized powder - **Solubility:** Freely soluble in water and aqueous buffers; partially soluble in dilute acetic acid solutions - **Storage:** −20 °C lyophilized; 4 °C for short-term aqueous use; avoid repeated freeze-thaw cycles

The nonapeptide sequence is highly conserved across mammalian species, consistent with its role as an endogenous signaling molecule. DSIP exists endogenously in both free and conjugated (bound to carrier proteins) forms in plasma, which partially explains its surprisingly long circulatory presence relative to its small molecular size.

---

Discovery and Historical Context

The initial isolation of DSIP represented a landmark in sleep research. Monnier and colleagues identified the peptide in 1977 while performing cross-transfusion experiments in rabbits: blood from electrically stimulated thalamic nuclei—which induced delta-wave sleep in donor rabbits—was transfused into recipient animals, who also fell into delta sleep. This bioassay guided the eventual purification and sequencing of the nonapeptide responsible for the effect.

Subsequent studies in the 1980s characterized DSIP's distribution throughout the mammalian central nervous system, hypothalamus, pituitary, thyroid, pancreas, and gastrointestinal tissues, indicating that it functions as more than a sleep-specific molecule. Its broad distribution suggested roles in multiple neuroendocrine and autonomic circuits. DSIP remains a subject of active preclinical investigation because its diverse biological activities make it a versatile probe of neuroendocrine signaling pathways.

---

Biological Actions — Sleep and Circadian Regulation

DSIP's original and best-characterized research application involves its effects on sleep architecture. In animal models:

- **Delta-wave induction:** Intracerebroventricular administration in rabbits increases slow-wave (stage 3–4 equivalent) sleep, reducing rapid sleep latency and extending non-REM sleep duration. - **Circadian entrainment:** DSIP plasma levels oscillate in a circadian pattern in both animals and humans, peaking during the subjective night, consistent with an endogenous role in sleep-phase timing. - **REM modulation:** Some preclinical data suggest DSIP influences the balance between REM and non-REM sleep, though findings have been less consistent than its non-REM effects. - **Hypnotic synergy:** DSIP has been examined in combination with other endogenous sleep factors (e.g., melatonin, interleukin-1β) to understand convergent pathways of sleep promotion.

Mechanistic hypotheses for DSIP's sleep effects include interactions with specific high-affinity central receptors (not yet fully characterized at the molecular level), modulation of gamma-aminobutyric acid (GABA) neurotransmission, and regulation of serotonergic and noradrenergic tone in brain regions that gate sleep transitions.

---

Neuroendocrine Modulation

Beyond sleep, DSIP has been studied as a multifaceted neuroendocrine regulator:

**Stress axis (HPA):** - DSIP appears to modulate the hypothalamic-pituitary-adrenal (HPA) axis, attenuating cortisol/corticosterone secretion in response to restraint and other stressors in rodent models. - Some studies report that DSIP normalizes aberrant corticotropin-releasing factor (CRF) activity under chronic stress conditions, suggesting a stress-buffering function.

**Growth hormone axis:** - Preclinical data indicate DSIP can potentiate growth hormone (GH) release from the pituitary under certain conditions, possibly by influencing hypothalamic somatostatin and/or GHRH signaling. This finding has generated interest in DSIP as a probe of somatotropic axis regulation.

**Pituitary hormones:** - Research in animal models has explored effects on luteinizing hormone (LH) and prolactin secretion, though results have varied across dosing protocols and experimental contexts.

**Thyroid and pancreatic tissues:** - DSIP-like immunoreactivity in thyroid and pancreatic islet cells implies possible paracrine roles in organ-level hormone secretion, though these peripheral actions remain less characterized than central effects.

---

Antioxidant and Neuroprotective Activity

A growing body of preclinical literature examines DSIP as an antioxidant and neuroprotective agent:

- **Reactive oxygen species (ROS) scavenging:** In vitro studies demonstrate that DSIP and its structural analogs can quench hydroxyl radicals and superoxide, reducing lipid peroxidation in neuronal membrane preparations. - **Mitochondrial protection:** Research in rodent models suggests DSIP attenuates oxidative damage to mitochondria in brain tissue following ischemia-reperfusion injury paradigms. - **Glutamate excitotoxicity:** Some preclinical work points to DSIP's ability to reduce neuronal death caused by excitotoxic glutamate challenge, possibly through modulation of calcium-dependent apoptotic pathways. - **Aging models:** DSIP has been investigated in aged rodent models as part of research programs on peptidergic interventions that reduce biomarkers of cellular aging and oxidative stress accumulation.

These antioxidant data have fueled interest in DSIP as a research tool for studying neuroprotection mechanisms, though the receptor targets mediating these effects remain an area of active investigation.

---

Analgesic and Anti-Stress Research

Animal studies have explored DSIP's modulation of pain processing and stress responses:

- **Opioid system interaction:** Some studies report that DSIP exerts analgesic effects in rodent pain models (hot-plate, tail-flick) and that these effects can be partially blocked by naloxone, suggesting cross-talk with endogenous opioid pathways—though DSIP itself does not appear to be a direct opioid receptor agonist. - **Stress-induced analgesia:** Research has examined whether DSIP contributes to the endogenous analgesia that accompanies certain stress states, consistent with its HPA-modulatory activity. - **Withdrawal and dependence models:** Preclinical studies have explored whether DSIP administration can attenuate signs of opioid withdrawal in animal models, connecting its neuroendocrine modulation to addiction neuroscience research.

---

Pharmacokinetic Properties

DSIP presents an unusual pharmacokinetic profile for a small nonapeptide:

- **Plasma half-life:** Approximately 30–40 minutes for the free peptide under standard conditions; the bound fraction may have prolonged biological availability. - **Blood-brain barrier (BBB) penetration:** DSIP crosses the BBB more readily than many other peptides of comparable molecular weight, possibly aided by active transport mechanisms. This property is important for understanding its central bioavailability following peripheral administration in animal models. - **Metabolic stability:** The peptide is subject to proteolytic cleavage by plasma and tissue peptidases; the Trp residue at position 1 is particularly susceptible, generating biologically active fragments in some studies. - **Active metabolites:** Cleavage products of DSIP have been reported to retain partial biological activity in some assays, complicating dose-response interpretations. - **Distribution:** Documented in plasma, CSF, hypothalamus, cortex, pituitary, spinal cord, and peripheral organs with DSIP-positive immunostaining.

---

Research Applications and Experimental Use

In preclinical settings, DSIP serves several research functions:

1. **Sleep architecture studies:** Characterizing delta-wave sleep induction, quantifying effects on sleep latency and duration via EEG polysomnography in rodent models. 2. **HPA axis modulation:** Examining stress-hormone blunting, cortisol regulation, and CRF circuitry in stressed or glucocorticoid-sensitized animals. 3. **Neuroprotection assays:** Testing cytoprotective effects in ischemia, excitotoxicity, or oxidative challenge models. 4. **Pain and opioid research:** Investigating opioid system interactions, analgesic mechanisms, and withdrawal attenuation paradigms. 5. **Aging and longevity research:** Using DSIP as a probe in rodent models examining peptidergic contributions to age-related decline in sleep quality and stress resilience. 6. **Receptor pharmacology:** DSIP is used as a ligand to probe the existence and functional characteristics of putative DSIP-specific receptors, which remain incompletely characterized despite decades of research.

---

Reconstitution and Handling (Research Use)

When preparing DSIP for in vitro or in vivo research:

- **Reconstitution:** Dissolve lyophilized DSIP in sterile water or physiological saline to achieve the desired stock concentration. Gentle agitation at room temperature is typically sufficient; do not heat. - **Concentration range:** Stock solutions of 1–5 mg/mL are common; dilute to working concentrations appropriate for the assay system. - **Vehicle compatibility:** Compatible with isotonic saline, PBS, and dilute acetic acid (for difficult reconstitutions); avoid strong organic solvents. - **Stability in solution:** Aqueous solutions are stable at 4 °C for 24–48 hours; for longer storage, aliquot and freeze at −80 °C to minimize freeze-thaw degradation. - **Sterile filtration:** For in vivo administration in animal models, filter reconstituted solutions through a 0.22 µm membrane. - **Avoid:** Direct UV exposure, oxidizing agents (the Trp residue is oxidation-sensitive), and repeated freeze-thaw cycles.

---

Regulatory and Research Status

DSIP is available exclusively for qualified preclinical research. It is not approved by the FDA, EMA, or any major regulatory agency for human therapeutic use, and it is not classified as a dietary supplement. All research applications must be conducted in compliance with applicable institutional, local, national, and international regulations governing the use of research peptides in laboratory settings.

This product is intended for **research use only (RUO)** by qualified scientists in appropriate laboratory environments. It is not for human consumption, veterinary use, or any other application outside of authorized research contexts.

---

Summary

DSIP (Delta Sleep-Inducing Peptide) is a historically significant nonapeptide that continues to attract research interest for its pleiotropic biological activities spanning sleep regulation, neuroendocrine modulation, antioxidant defense, neuroprotection, and pain processing. Its ability to cross the blood-brain barrier, its circadian-patterned endogenous expression, and its diverse receptor interactions make it a valuable tool for investigating fundamental questions in neuroscience, sleep medicine, and stress biology. The synthetic 5mg lyophilized form provides researchers with a well-characterized reagent for designing and executing rigorous preclinical studies. All use is strictly for authorized research purposes.